Journal article

Therapeutic efficacy of antibodies lacking FcγR against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies

  • Williams, Katherine L. Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, California, United States of America
  • Sukupolvi-Petty, Soila Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America
  • Beltramello, Martina Institute for Research in Biomedicine (IRB), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
  • Johnson, Syd Macrogenics, Inc., Rockville, Maryland, United States of America
  • Sallusto, Federica Institute for Research in Biomedicine (IRB), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
  • Lanzavecchia, Antonio Institute for Research in Biomedicine (IRB), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
  • Diamond, Michael S. Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America
  • Harris, Eva Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, California, United States of America
Show more…
    14.02.2013
Published in:
  • Plos pathogens. - 2013, vol. 9, no. 2, p. e1003157
English Dengue hemorrhagic fever and dengue shock syndrome (DHF/DSS) are life-threatening complications following infection with one of the four serotypes of dengue virus (DENV). At present, no vaccine or antiviral therapies are available against dengue. Here, we characterized a panel of eight human or mouse-human chimeric monoclonal antibodies (MAbs) and their modified variants lacking effector function and dissected the mechanism by which some protect against antibody-enhanced lethal DENV infection. We found that neutralizing modified MAbs that recognize the fusion loop or the A strand epitopes on domains II and III of the envelope protein, respectively, act therapeutically by competing with and/or displacing enhancing antibodies. By analyzing these relationships, we developed a novel in vitro suppression-of- enhancement assay that predicts the ability of modified MAbs to act therapeutically against antibody-enhanced disease in vivo. These studies provide new insight into the biology of DENV pathogenesis and the requirements for antibodies to treat lethal DENV disease.
Language
  • English
Classification
Medicine
License
License undefined
Identifiers
Persistent URL
https://susi.usi.ch/usi/documents/319191
Statistics

Document views: 6 File downloads:
  • Williams_PP_2013.pdf: 2